These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16544172)

  • 1. Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease.
    Usami T; Kimura G
    Clin Exp Nephrol; 2006 Mar; 10(1):8-12. PubMed ID: 16544172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan.
    Usami T; Nakao N; Fukuda M; Takeuchi O; Kamiya Y; Yoshida A; Kimura G
    Kidney Int; 2003 Oct; 64(4):1445-9. PubMed ID: 12969164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different regional dynamics of end-stage renal disease in Japan by different causes.
    Kato N; Usami T; Fukuda M; Motokawa M; Kamiya Y; Yoshida A; Kimura G
    Nephrology (Carlton); 2005 Aug; 10(4):400-4. PubMed ID: 16109089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional differences in end-stage renal disease and amount of protein intake in Japan.
    Motokawa M; Fukuda M; Muramatsu W; Sengo K; Kato N; Usami T; Yoshida A; Kimura G
    J Ren Nutr; 2007 Mar; 17(2):118-25. PubMed ID: 17321951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
    Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
    Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Nagata M; Tsuchimoto A; Hirakata H; Kitazono T; Tsuruya K
    Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low birth weight and end-stage renal disease: demographic analysis by region in Japan.
    Ichikawa T; Fukuda M; Wakamatsu-Yamanaka T; Sato R; Naito T; Togawa H; Sasakawa Y; Tomonari T; Mizuno M; Miura T; Kato Y; Ono M; Shirasawa Y; Ito A; Yoshida A; Kimura G
    Clin Exp Nephrol; 2012 Aug; 16(4):596-603. PubMed ID: 22302087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause.
    Wakai K; Nakai S; Kikuchi K; Iseki K; Miwa N; Masakane I; Wada A; Shinzato T; Nagura Y; Akiba T
    Nephrol Dial Transplant; 2004 Aug; 19(8):2044-52. PubMed ID: 15173379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE-inhibitor use and the long-term risk of renal failure in diabetes.
    Suissa S; Hutchinson T; Brophy JM; Kezouh A
    Kidney Int; 2006 Mar; 69(5):913-9. PubMed ID: 16518351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographic differences in the increasing ESRD rate have disappeared in Japan.
    Wakamatsu-Yamanaka T; Fukuda M; Sato R; Naito T; Togawa H; Tomonari T; Kato Y; Miura T; Mizuno M; Ichikawa T; Miyagi S; Shirasawa Y; Ito A; Yoshida A; Kimura G
    Clin Exp Nephrol; 2011 Oct; 15(5):708-713. PubMed ID: 21638004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
    de Zeeuw D; Ramjit D; Zhang Z; Ribeiro AB; Kurokawa K; Lash JP; Chan J; Remuzzi G; Brenner BM; Shahinfar S
    Kidney Int; 2006 May; 69(9):1675-82. PubMed ID: 16572114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional variations in the incidence of end-stage renal failure in Japan.
    Usami T; Koyama K; Takeuchi O; Morozumi K; Kimura G
    JAMA; 2000 Nov 22-29; 284(20):2622-4. PubMed ID: 11086370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease.
    Lovati E; Richard A; Frey BM; Frey FJ; Ferrari P
    Kidney Int; 2001 Jul; 60(1):46-54. PubMed ID: 11422735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing end stage renal disease in diabetic patients--genetic aspect (part I).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):1-14. PubMed ID: 16088846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Integrated care and expected outcomes over the progression of CKD (chronic kidney disease)].
    Kimura G
    Nihon Rinsho; 2008 Sep; 66(9):1807-13. PubMed ID: 18788414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.